About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
PMID: 35029330 Journal: PEDIATRIC BLOOD & CANCER Year: 2022 Reference: Pediatr Blood Cancer. 2022 Aug;69(8):e29551. doi: 10.1002/pbc.29551. Epub 2022 Jan 14. Impact factor: 3.167 Publication type: Paper in international publication Authors: Cortes, Marta, Carceller, Fernando, Rubio-San-Simon, Alba, Vaidya, Sucheta J, Bautista, Francisco, Moreno, Lucas et al. DOI: 10.1002/pbc.29551
PMID: 34077956 Journal: NEURO-ONCOLOGY Year: 2021 Reference: Neuro Oncol. 2021 Sep 1;23(9):1597-1611. doi: 10.1093/neuonc/noab136. Impact factor: 12.3 Publication type: Paper in international publication Authors: von Hoff, Katja, Snuderl, Matija, Zheludkova, Olga, Golanov, Andrey, Okonechnikov, Konstantin, Mynarek, Martin, Juhnke, B Ole, Rutkowski, Stefan, Schuller, Ulrich, Pizer, Barry et al. DOI: 10.1093/neuonc/noab136
PMID: 34076861 Journal: Clinical & Translational Oncology Year: 2021 Reference: Clin Transl Oncol. 2021 Dec;23(12):2489-2496. doi: 10.1007/s12094-021-02649-y. Epub 2021 Jun 2. Impact factor: 3.405 Publication type: Paper in international publication Authors: Canete, A, Rives, S, Perez-Martinez, A, Mora, J, Patino-Garcia, A, Lassaleta, A, Llort, A, Ramirez, M, Mata, C, Gallego, S et al. DOI: 10.1007/s12094-021-02649-y
PMID: 34025429 Journal: Frontiers in Pharmacology Year: 2021 Reference: Front Pharmacol. 2021 May 5;12:670945. doi: 10.3389/fphar.2021.670945. eCollection 2021. Impact factor: 5.811 Publication type: Paper in international publication Authors: Amaro-Hosey, Kristopher, Danes, Immaculada, Vendrell, Lourdes, Alonso, Laura, Renedo, Berta, Gros, Luis, Vidal, Xavier, Cereza, Gloria, Agusti, Antonia et al. DOI: 10.3389/fphar.2021.670945
PMID: 33984160 Journal: AMERICAN JOURNAL OF HEMATOLOGY Year: 2021 Reference: Am J Hematol. 2021 Aug 1;96(8):989-999. doi: 10.1002/ajh.26234. Epub 2021 May 25. Impact factor: 10.047 Publication type: Paper in international publication Authors: Ramirez, Maria Jose, Pujol, Roser, Trujillo-Quintero, Juan Pablo, Minguillon, Jordi, Bogliolo, Massimo, Rio, Paula, Navarro, Susana, Casado, Jose A, Badell, Isabel, Carrasco, Estela et al. DOI: 10.1002/ajh.26234
PMID: 31799703 Journal: CLINICAL AND EXPERIMENTAL IMMUNOLOGY Year: 2020 Reference: Clin Exp Immunol. 2020 Apr;200(1):61-72. doi: 10.1111/cei.13405. Epub 2020 Jan 19. Impact factor: 3.532 Publication type: Paper in international publication Authors: Alonso, Laura, Riviere, Jacques G, Soler-Palacin, Pere, Colobran, Roger, Sayos, Joan, Martinez-Gallo, Monica, Franco-Jarava, Clara, Ossowski, Stephan, Drechsel, Oliver, Magallon-Lorenz, Miriam et al. DOI: 10.1111/cei.13405
PMID: 31586946 Journal: JOURNAL OF MEDICAL GENETICS Year: 2020 Reference: J Med Genet. 2020 Apr;57(4):258-268. doi: 10.1136/jmedgenet-2019-106249. Epub 2019 Oct 5. Impact factor: 4.943 Publication type: Paper in international publication Authors: Molines, Antonio, Perez de Soto, Inmaculada, Hernando, Ines, Munoz, Juan Antonio, Del Rosario Marin, Maria, Balmana, Judith, Stjepanovic, Neda, Carrasco, Estela, Cuesta, Isabel, Cosuelo, Jose Miguel et al. DOI: 10.1136/jmedgenet-2019-106249
PMID: 32273586 Journal: BONE MARROW TRANSPLANTATION Year: 2020 Reference: Bone Marrow Transplant. 2020 Sep;55(9):1884. doi: 10.1038/s41409-020-0901-x. Impact factor: 4.725 Publication type: Letter or abstract Authors: Gungor, Tayfun, Salim, Rahuman, Tischer, Johanna, Tecchio, Cristina, Russell, Nigel, Chybicka, Alicja, Styczynski, Jan, Krivan, Gergely, Smith, Owen, Stein, Jerry et al. DOI: 10.1038/s41409-020-0901-x
PMID: 32203263 Journal: BONE MARROW TRANSPLANTATION Year: 2020 Reference: Bone Marrow Transplant. 2020 Aug;55(8):1540-1551. doi: 10.1038/s41409-020-0854-0. Epub 2020 Mar 17. Impact factor: 4.725 Publication type: Paper in international publication Authors: Willasch, Andre Manfred, Peters, Christina, Sedlacek, Petr, Dalle, Jean-Hugues, Kitra-Roussou, Vassiliki, Yesilipek, Akif, Wachowiak, Jacek, Lankester, Arjan, Prete, Arcangelo, Hamidieh, Amir Ali et al. DOI: 10.1038/s41409-020-0854-0
The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.
The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.
During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.
